FIELD: medicine.
SUBSTANCE: present group of inventions refers to medicine, namely to oncology, and concerns treating lung cancer with folic acid receptor alpha (FRA) expression. That is ensured by determining the FRA expression level in the patient's biological sample and comparing it with the reference standard. If the patient's FRA expression level is equal to or exceeds the reference level, treatment is ensured by introducing an antibody that binds immunorelectively to the FRA receptor.
EFFECT: invention provides effective treatment of lung cancer in the given group of patients due to individual selection of the optimal type of drug therapy.
30 cl, 5 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO FOLIC ACID RECEPTOR 1, THEIR IMMUNOCONJUGATES AND APPLICATION | 2011 |
|
RU2610663C2 |
| NEW MODULATORS AND METHODS OF THEIR APPLICATION | 2012 |
|
RU2627176C2 |
| NOVEL MODULATORS AND METHODS FOR USE THEREOF | 2011 |
|
RU2592672C9 |
| AGENTS LINKING FRIZZLED RECEPTOR AND THEIR USE | 2009 |
|
RU2579897C2 |
| DIAGNOSTIC ASSAYS AND KITS FOR DETECTION OF FOLATE RECEPTOR 1 | 2013 |
|
RU2668824C2 |
| HUMANISED ANTI-CXCR4 ANTIBODIES FOR TREATING CANCER | 2011 |
|
RU2595394C2 |
| FOLATE RECEPTOR ALPHA AS A DIAGNOSTIC AND PROGNOSTIC MARKER OF MALIGNANT TUMOURS EXPRESSING FOLATE RECEPTOR ALPHA | 2011 |
|
RU2764592C2 |
| FUEL ACID ALPHA RECEPTOR AS DIAGNOSTIC AND PREDICTIVE MARKER OF MALIGNANT TUMOURS EXPRESSING ALPHA FONIUM ACID RECEPTOR | 2011 |
|
RU2630608C2 |
| ANTIBODIES AND ANALYSIS METHODS FOR FOLIC ACID 1 RECEPTOR DETECTION | 2014 |
|
RU2725825C2 |
| ANTI-cMet ANTIBODY AND USE THEREOF FOR DETECTION AND DIAGNOSIS OF CANCER | 2010 |
|
RU2582265C2 |
